The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in Vivo

Huei Leng Helena Ng, Aiping LYU, Ge Lin, Ling Qin, Zhijun YANG*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)
1 Downloads (Pure)

Abstract

Drug delivery nanocarriers, especially targeted drug delivery by liposomes are emerging as a class of therapeutics for cancer. Early research results suggest that liposomal therapeutics enhanced efficacy, while simultaneously reducing side effects, owing to properties such as more targeted localization in tumors and active cellular uptake. Here, we highlight the features of immunoliposomes that distinguish them from previous anticancer therapies, and describe how these features provide the potential for therapeutic effects that are not achievable with other modalities. While a large number of studies has been published, the emphasis here is placed on the carbonic anhydrase IX (CA-IX) and the conjugated liposomes that are likely to open a new chapter on drug delivery system by using immunoliposomes to deliver anticancer ingredients to cancer cells in vivo.

Original languageEnglish
Pages (from-to)230-255
Number of pages26
JournalInternational Journal of Molecular Sciences
Volume16
Issue number1
DOIs
Publication statusPublished - 24 Dec 2014

Scopus Subject Areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

User-Defined Keywords

  • Anticancer ingredients
  • Cancer cell penetrating peptides
  • Carbonic anhydronase IX (CA-IX)
  • Immunoliposomes
  • In vivo delivery

Fingerprint

Dive into the research topics of 'The potential of liposomes with carbonic anhydrase IX to deliver anticancer ingredients to cancer cells in Vivo'. Together they form a unique fingerprint.

Cite this